Title:
癌治療用医薬組成物
Document Type and Number:
Japanese Patent JP6501171
Kind Code:
B2
Abstract:
The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
Inventors:
Tetsuya Yoshida
Yujiro Kitani
Mitsufumi Matsumoto
Takayuki Kanazawa
Satomi Shinonome
Hojo Kanji
Eiya Okura
Shimon Sakaguchi
Jun Tanaka
Nao Wada
Atsushi Kawashima
Nonomura Norio
Yujiro Kitani
Mitsufumi Matsumoto
Takayuki Kanazawa
Satomi Shinonome
Hojo Kanji
Eiya Okura
Shimon Sakaguchi
Jun Tanaka
Nao Wada
Atsushi Kawashima
Nonomura Norio
Application Number:
JP2018551478A
Publication Date:
April 17, 2019
Filing Date:
March 28, 2018
Export Citation:
Assignee:
Shionogi Pharmaceutical Co., Ltd.
National University Corporation Osaka University
National University Corporation Osaka University
International Classes:
A61K39/395; A61P35/00; A61P37/04; A61P43/00
Foreign References:
| WO2015179236A1 | ||||
| WO2007044756A2 | ||||
| WO2013131010A2 | ||||
| WO2018112032A1 |
Other References:
PLITAS, G. et al.,Preferential expression of the chemokine receptor 8 (CCR8) on regulatory T cells (Treg) infiltrating human breast cancers represents a novel immunotherapeutic target,Cancer Research [on line],2016年 2月,Vol.76, No.4, Supp.1,Abstract P4-04-11,[retrieved on 2018.06.18], [Retrieved from the Internet:
Immunity,2016年,Vol.45,pp.1122-1134
SUGIYAMA, D. et al.,Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans,PNAS,2013年10月29日,Vol.110, No.44,pp.17945-17950
HOELZINGER, D.B. et al.,Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses,Journal of Immunology,2010年,Vol.184, No.12,pp.6833-6842
Immunity,2016年,Vol.45,pp.1122-1134
SUGIYAMA, D. et al.,Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans,PNAS,2013年10月29日,Vol.110, No.44,pp.17945-17950
HOELZINGER, D.B. et al.,Blockade of CCL1 Inhibits T Regulatory Cell Suppressive Function Enhancing Tumor Immunity without Affecting T Effector Responses,Journal of Immunology,2010年,Vol.184, No.12,pp.6833-6842
Attorney, Agent or Firm:
Kenichi Sugita
Hideaki Watanabe
Hideaki Watanabe